Prescription-grade crystalline glucosamine sulfate as an add-on therapy to conventional treatments in erosive osteoarthritis of the hand: results from a 6-month observational retrospective study

Sara Tenti, Nicola Veronese, Sara Cheleschi, Iole Seccafico, Olivier Bruyère, Jean-Yves Reginster, Antonella Fioravanti, Sara Tenti, Nicola Veronese, Sara Cheleschi, Iole Seccafico, Olivier Bruyère, Jean-Yves Reginster, Antonella Fioravanti

Abstract

Objective: To evaluate the efficacy of prescription-grade Crystalline Glucosamine Sulfate (pCGS) as an add-on treatment to conventional therapy, compared to usual therapy alone, in patients with erosive osteoarthritis of the hand (EHOA).

Methods: This 6-month retrospective case-control study included patients with concomitant knee osteoarthritis and symptomatic EHOA. Participants were stratified into two groups based on whether or not pCGS (1500 mg/day) was added to the conventional therapy (education and training in ergonomic principles, exercise and use on-demand of symptomatic drugs) for hand osteoarthritis. Patients were evaluated at baseline, after 3 and 6 months. Primary outcomes were the change from baseline to month 6 in Visual Analogue Scale (VAS) hand pain and in Functional Index for Hand Osteoarthritis (FIHOA) score. A set of secondary parameters was also evaluated.

Results: 123 patients were included as follows: 67 treated with pCGS in addition to conventional therapy (pCGS Group) and 56 with conventional therapy alone (Control Group). After 6 months a significant difference in VAS and in FIHOA score (p < 0.01 and p < 0.001, respectively) was observed in favor of pCGS Group. Similar results were found for morning stiffness duration (p < 0.05), health assessment questionnaire (p < 0.01) and physical and mental component score of 36-item short form (p < 0.05 and p < 0.001, respectively). A significant reduction of symptomatic drug consumption at 3 and 6 months was reported in the pCGS Group (p < 0.001). No serious adverse event was recorded in both groups.

Conclusions: Despite all the limitations inherent to an observational study, our results suggest the potential effectiveness of pCGS, when used in combination with conventional therapy in EHOA. Further randomized placebo-controlled trials are needed to confirm these positive findings.

Trial registration: ClinicalTrials.gov, http://www.

Clinicaltrials: gov , date of registration: February 2, 2022, NCT05237596. The present trial was retrospectively registered.

Keywords: Erosive hand osteoarthritis; Hand osteoarthritis; Pain; Prescription-grade crystalline glucosamine sulfate; Retrospective study; Symptomatic slow-acting drugs for osteoarthritis.

Conflict of interest statement

On behalf of all authors, the corresponding author states that there is no conflict of interest.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Flow diagram of the study population. OA osteoarthritis, pCGS prescription-grade crystalline glucosamine sulfate; DMARDs disease modifying anti-rheumatic drug
Fig. 2
Fig. 2
Means with standard error changes in the Visual Analogue Scale (VAS) (0–100 mm) (a), and in the Functional Index for Hand Osteoarthritis (FIHOA) score (0–30) (b), after 3 and 6 months in prescription-grade Crystalline Glucosamine sulfate (pCGS)-exposed Group and pCGS-unexposed Group. pCGS-exposed Group vs pCGS-unexposed Group: *p < 0.05; **p < 0.01; ***p < 0.001
Fig. 3
Fig. 3
Means with standard error changes in morning stiffness, measured by Visual Analogue Scale (VAS) (minutes) (a), in the Health Assessment Questionnaire (HAQ) (0–3) (b), in the Physical Component Score (PCS) of the Short-Form Survey 36 (SF-36) (c), and in the Mental Component Score (MCS) of SF-36 (d), after 3 and 6 months in prescription-grade Crystalline Glucosamine Sulfate (pCGS)-exposed Group and pCGS-unexposed Group. pCGS-exposed Group vs pCGS-unexposed Group: *p < 0.05; **p < 0.001; ***p < 0.001

References

    1. Qin J, Barbour KE, Murphy LB, Nelson AE, Schwartz TA, Helmick CG, et al. Lifetime Risk of Symptomatic Hand Osteoarthritis: The Johnston County Osteoarthritis Project. Arthritis Rheumatol. 2017;69:1204–1212. doi: 10.1002/art.40097.
    1. Arthritis Foundation (2019) Osteoarthritis of the Hands.
    1. Addimanda O, Mancarella L, Dolzani P, Punzi L, Fioravanti A, Pignotti E, Meliconi R. Clinical and radiographic distribution of structural damage in erosive and nonerosive hand osteoarthritis. Arthritis Care Res (Hoboken) 2012;64:1046–1053. doi: 10.1002/acr.21658.
    1. Gazeley DJ, Yeturi S, Patel PJ, Rosenthal AK. Erosive osteoarthritis: A systematic analysis of definitions used in the literature. Semin Arthritis Rheum. 2017;46:395–403. doi: 10.1016/j.semarthrit.2016.08.013.
    1. Marshall M, Watt FE, Vincent TL, Dziedzic K. Hand osteoarthritis: clinical phenotypes, molecular mechanisms and disease management. Nat Rev Rheumatol. 2018;14:641–656. doi: 10.1038/s41584-018-0095-4.
    1. Favero M, Belluzzi E, Ortolan A, Lorenzin M, Oliviero F, Doria A, et al. Erosive hand osteoarthritis: latest findings and outlook. Nat Rev Rheumatol. 2022 doi: 10.1038/s41584-021-00747-3.
    1. Marshall M, Nicholls E, Kwok WY, Peat G, Kloppenburg M, van der Windt D, et al. Erosive osteoarthritis: a more severe form of radiographic hand osteoarthritis rather than a distinct entity? Ann Rheum Dis. 2015;74:136–141. doi: 10.1136/annrheumdis-2013-203948.
    1. Poletto E, Tinazzi I, Marchetta A, Smania N, Rossato E. Hand erosive osteoarthritis and distal interphalangeal involvement in psoriatic arthritis: the place of conservative therapy. J Clin Med. 2021;10:2630. doi: 10.3390/jcm10122630.
    1. Tenti S, Ferretti F, Gusinu R, Gallo I, Giannotti S, Pozza A, et al. Impact of thumb osteoarthritis on pain, function, and quality of life: a comparative study between erosive and non-erosive hand osteoarthritis. Clin Rheumatol. 2020;39:2195–2206. doi: 10.1007/s10067-020-04982-z.
    1. McAlindon TE, Driban JB, Roberts MB, Duryea J, Haugen IK, Schaefer LF, et al. Erosive hand osteoarthritis: incidence and predictive characteristics among participants in the osteoarthritis initiative. Arthritis Rheumatol. 2021;73:2015–2024. doi: 10.1002/art.41757.
    1. Verbruggen G, Wittoek R, Vander Cruyssen B, Elewaut D. Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification. Ann Rheum Dis. 2012;71:891–898. doi: 10.1136/ard.2011.149849.
    1. Chevalier X, Ravaud P, Maheu E, et al.; French Section of Osteoarthritis (2015) Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial. Ann Rheum Dis 74:1697–1705. 10.1136/annrheumdis-2014-205348
    1. Aitken D, Laslett LL, Pan F, Haugen IK, Otahal P, Bellamy N, et al. A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis - the HUMOR trial. Osteoarthr Cartil. 2018;26:880–887. doi: 10.1016/j.joca.2018.02.899.
    1. Kingsbury SR, Tharmanathan P, Keding A, Ronaldson SJ, Grainger A, Wakefield RJ, et al. Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis: a randomized trial. Ann Intern Med. 2018;168:385–395. doi: 10.7326/M17-1430.
    1. Kloppenburg M, Ramonda R, Bobacz K, Kwok WY, Elewaut D, Huizinga TWJ, et al. Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018;77:1757–1764. doi: 10.1136/annrheumdis-2018-213202.
    1. Lee W, Ruijgrok L, Boxma-de Klerk B, Kok MR, Kloppenburg M, Gerards A, et al. Efficacy of hydroxychloroquine in hand osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken) 2018;70:1320–1325. doi: 10.1002/acr.23471.
    1. Kloppenburg M, Peterfy C, Haugen IK, Kroon F, Chen S, Wang L, et al. Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. Ann Rheum Dis. 2019;78:413–420. doi: 10.1136/annrheumdis-2018-213336.
    1. Richette P, Latourte A, Sellam J, Wendling D, Piperno M, Goupille P, et al. Efficacy of tocilizumab in patients with hand osteoarthritis: double blind, randomised, placebo-controlled, multicentre trial. Ann Rheum Dis. 2020 doi: 10.1136/annrheumdis-2020-218547.
    1. Ferrero S, Wittoek R, Allado E, Cruzel C, Fontas E, Breuil V, et al. Methotrexate treatment in hand osteoarthritis refractory to usual treatments: a randomised, double-blind, placebo-controlled trial. Semin Arthritis Rheum. 2021;51:831–838. doi: 10.1016/j.semarthrit.2021.04.016.
    1. Kedor C, Detert J, Rau R, Wassenberg S, Listing J, Klaus P, et al. Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands: results of the OA-TREAT study-a randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. RMD Open. 2021;7:e001660. doi: 10.1136/rmdopen-2021-001660.
    1. Kloppenburg M, Kroon FP, Blanco FJ, Doherty M, Dziedzic KS, Greibrokk E, et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019;78:16–24. doi: 10.1136/annrheumdis-2018-213826.
    1. Gabay C, Medinger-Sadowski C, Gascon D, Kolo F, Finckh A. Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single center. Arthritis Rheum. 2011;63:3383–3391. doi: 10.1002/art.30574.
    1. Rovetta G, Monteforte P, Molfetta G, Balestra V. A two-year study of chondroitin sulfate in erosive osteoarthritis of the hands: behavior of erosions, osteophytes, pain and hand dysfunction. Drugs Exp Clin Res. 2004;30:11–16.
    1. Largo R, Alvarez-Soria MA, Díez-Ortego I, Calvo E, Sánchez-Pernaute O, Egido J, Herrero-Beaumont G. Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthr Cartil. 2003;11:290–298. doi: 10.1016/s1063-4584(03)00028-1.
    1. Cheleschi S, Tenti S, Giannotti S, Veronese N, Reginster JY, Fioravanti A. A combination of celecoxib and glucosamine sulfate has anti-inflammatory and chondroprotective effects: results from an in vitro study on human osteoarthritic chondrocytes. Int J Mol Sci. 2021;22:8980. doi: 10.3390/ijms22168980.
    1. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001;357:251–256. doi: 10.1016/S0140-6736(00)03610-2.
    1. Pavelka K, Bruyere O, Rovati LC, Olejárova M, Giacovelli G, Reginster JY. Relief in mild-to-moderate pain is not a confounder in joint space narrowing assessment of full extension knee radiographs in recent osteoarthritis structure-modifying drug trials. Osteoarthr Cartil. 2003;11:730–737. doi: 10.1016/s1063-4584(03)00166-3.
    1. Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005 doi: 10.1002/14651858.CD002946.pub2.
    1. Herrero-Beaumont G, Ivorra JA, Del Carmen TM, Blanco FJ, Benito P, et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum. 2007;56:555–567. doi: 10.1002/art.22371.
    1. Giordano N, Fioravanti A, Papakostas P, Montella A, Giorgi G, Nuti R. The efficacy and tolerability of glucosamine sulfate in the treatment of knee osteoarthritis: A randomized, double-blind, placebo-controlled trial. Curr Ther Res Clin Exp. 2009;70:185–196. doi: 10.1016/j.curtheres.2009.05.004.
    1. Bruyère O, Reginster JY, Honvo G, Detilleux J. Cost-effectiveness evaluation of glucosamine for osteoarthritis based on simulation of individual patient data obtained from aggregated data in published studies. Aging Clin Exp Res. 2019;31:881–887. doi: 10.1007/s40520-019-01138-1.
    1. Bruyère O, Cooper C, Pelletier JP, Branco J, Luisa Brandi M, Guillemin F, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) Semin Arthritis Rheum. 2014;44:253–263. doi: 10.1016/j.semarthrit.2014.05.014.
    1. Bruyère O, Cooper C, Pelletier JP, Maheu E, Rannou F, Branco J, et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016;45:S3–11. doi: 10.1016/j.semarthrit.2015.11.010.
    1. Bruyère O, Honvo G, Veronese N, Arden NK, Branco J, Curtis EM, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) Semin Arthritis Rheum. 2019;49:337–350. doi: 10.1016/j.semarthrit.2019.04.008.
    1. Tenti S, Giordano N, Mondanelli N, Giannotti S, Maheu E, Fioravanti A. A retrospective observational study of glucosamine sulfate in addition to conventional therapy in hand osteoarthritis patients compared to conventional treatment alone. Aging Clin Exp Res. 2020;32:1161–1172. doi: 10.1007/s40520-019-01305-4.
    1. Agenzia Italiana del Farmaco (AIFA). Guideline for the classification and conduction of the observational studies on medicines. . Accessed 30 Mar 2022
    1. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986;29:1039–1049. doi: 10.1002/art.1780290816.
    1. Fioravanti A, Cheleschi S, De Palma A, Addimanda O, Mancarella L, Pignotti E, et al. Can adipokines serum levels be used as biomarkers of hand osteoarthritis? Biomarkers. 2018;23:265–270. doi: 10.1080/1354750X.2017.1401665.
    1. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957;16:494–502. doi: 10.1136/ard.16.4.494.
    1. Østerås N, Hagen KB, Grotle M, Sand-Svartrud AL, Mowinckel P, Aas E, Kjeken I. Exercise programme with telephone follow-up for people with hand osteoarthritis - protocol for a randomised controlled trial. BMC Musculoskelet Disord. 2014;15:82. doi: 10.1186/1471-2474-15-82.
    1. Østerås N, Kjeken I, Smedslund G, Moe RH, Slatkowsky-Christensen B, Uhlig T, Hagen KB. Exercise for hand osteoarthritis: a cochrane systematic review. J Rheumatol. 2017;44:1850–1858. doi: 10.3899/jrheum.170424.
    1. Ariani A, Manara M, Fioravanti A, Iannone F, Salaffi F, Ughi N, et al. The Italian Society for Rheumatology clinical practice guidelines for the diagnosis and management of knee, hip and hand osteoarthritis. Reumatismo. 2019;71:5–21. doi: 10.4081/reumatismo.2019.1188.
    1. Dreiser RL, Maheu E, Guillou GB. Sensitivity to change of the functional index for hand osteoarthritis. Osteoarthr Cartil. 2000;8:S25–S28. doi: 10.1053/joca.2000.0332.
    1. Gandini F, Giannitti C, Fattore G, Giordano N, Galeazzi M, Fioravanti A. Validation of an Italian version of the functional index for hand osteoarthritis (FIHOA) Mod Rheumatol. 2012;22:758–765. doi: 10.1007/s10165-011-0579-4.
    1. Ranza R, Marchesoni A, Calori G, Bianchi G, Braga M, Canazza S, et al. The Italian version of the Functional Disability Index of the Health Assessment Questionnaire. A reliable instrument for multicenter studies on rheumatoid arthritis. Clin Exp Rheumatol. 1993;11:123–128.
    1. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes. 2003;1:20. doi: 10.1186/1477-7525-1-20.
    1. Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–483. doi: 10.1097/00005650-199206000-00002.
    1. Apolone G, Mosconi P. The Italian SF-36 health survey: translation, validation and norming. J Clin Epidemiol. 1998;51:1025–1036. doi: 10.1016/s0895-4356(98)00094-8.
    1. Pham T, van der Heijde D, Altman RD, Anderson JJ, Bellamy N, Hochberg M, et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthr Cartil. 2004;12:389–399. doi: 10.1016/j.joca.2004.02.001.
    1. Bijsterbosch J, Watt I, Meulenbelt I, Rosendaal FR, Huizinga TW, Kloppenburg M. Clinical burden of erosive hand osteoarthritis and its relationship to nodes. Ann Rheum Dis. 2010;69:1784–1788. doi: 10.1136/ard.2009.125435.
    1. Michon M, Maheu E, Berenbaum F. Assessing health-related quality of life in hand osteoarthritis: a literature review. Ann Rheum Dis. 2011;70:921–928. doi: 10.1136/ard.2010.131151.
    1. Bruyere O, Pavelka K, Rovati LC, Gatterová J, Giacovelli G, Olejarová M, et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthr Cartil. 2008;16:254–260. doi: 10.1016/j.joca.2007.06.011.
    1. Rovati LC, Girolami F, D'Amato M, Giacovelli G. Effects of glucosamine sulfate on the use of rescue non-steroidal anti-inflammatory drugs in knee osteoarthritis: Results from the Pharmaco-Epidemiology of GonArthroSis (PEGASus) study. Semin Arthritis Rheum. 2016;45:S34–41. doi: 10.1016/j.semarthrit.2015.10.009.
    1. Fioravanti A, Fabbroni M, Cerase A, Galeazzi M. Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study. Rheumatol Int. 2009;29:961–965. doi: 10.1007/s00296-009-0872-0.
    1. Fioravanti A, Tenti S, McAllister M, Chemaly M, Eakin A, McLaughlin J, et al. Exploring the Involvement of NLRP3 and IL-1β in Osteoarthritis of the Hand: Results from a Pilot Study. Mediators Inflamm. 2019;2019:2363460. doi: 10.1155/2019/2363460.
    1. Davis CR, Ruediger CD, Dyer KA, Lester S, Graf SW, Kroon FPB, et al. Colchicine is not effective for reducing osteoarthritic hand pain compared to placebo: a randomised, placebo-controlled trial (COLAH) Osteoarthr Cartil. 2021;29:208–214. doi: 10.1016/j.joca.2020.11.002.
    1. Saviola G, Abdi-Ali L, Campostrini L, Sacco S, Baiardi P, Manfredi M, et al. Clodronate and hydroxychloroquine in erosive osteoarthritis: a 24-month open randomized pilot study. Mod Rheumatol. 2012;22:256–263. doi: 10.1007/s10165-011-0506-8.
    1. Saviola G, Abdi-Ali L, Povino MR, Campostrini L, Sacco S, Dalle Carbonare L, Carbonare LD. Intramuscular clodronate in erosive osteoarthritis of the hand is effective on pain and reduces serum COMP: a randomized pilot trial-The ER.O.D.E. study (ERosive Osteoarthritis and Disodium-clodronate Evaluation) Clin Rheumatol. 2017;36:2343–2350. doi: 10.1007/s10067-017-3681-y.
    1. Felson DT, Neogi T. Emerging treatment models in rheumatology: challenges for osteoarthritis trials. Arthritis Rheumatol. 2018;70:1175–1181. doi: 10.1002/art.40515.
    1. Kucharz EJ, Kovalenko V, Szántó S, Bruyère O, Cooper C, Reginster JY. A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes. Curr Med Res Opin. 2016;32:997–1004. doi: 10.1185/03007995.2016.1154521.
    1. Bruyère O, Cooper C, Al-Daghri NM, Dennison EM, Rizzoli R, Reginster JY. Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) Aging Clin Exp Res. 2018;30:111–117. doi: 10.1007/s40520-017-0861-1.
    1. Reginster JL, Bruyere O, Cooper C. Different glucosamine sulfate products generate different outcomes on osteoarthritis symptoms. Ann Rheum Dis. 2018;77:e39. doi: 10.1136/annrheumdis-2017-212251.
    1. Veronese N, Demurtas J, Smith L, et al.; on behalf on the European Geriatric Medicine Society Special Interest Groups in Systematic Reviews and Meta-Analyses and Arthritis (2020) Glucosamine sulphate: an umbrella review of health outcomes. Ther Adv Musculoskelet Dis 12:1759720X20975927. 10.1177/1759720X20975927
    1. Persiani S, Roda E, Rovati LC, Locatelli M, Giacovelli G, Roda A. Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthr Cartil. 2005;13:1041–1049. doi: 10.1016/j.joca.2005.07.009.
    1. Persiani S, Rotini R, Trisolino G, Rovati LC, Locatelli M, Paganini D, et al. Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose. Osteoarthr Cartil. 2007;15:764–772. doi: 10.1016/j.joca.2007.01.019.
    1. Chiusaroli R, Piepoli T, Zanelli T, Ballanti P, Lanza M, Rovati LC, Caselli G. Experimental pharmacology of glucosamine sulfate. Int J Rheumatol. 2011;2011:939265. doi: 10.1155/2011/939265.
    1. Bruyère O, Altman RD, Reginster JY. Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016;45:S12–17. doi: 10.1016/j.semarthrit.2015.11.011.
    1. Gregori D, Giacovelli G, Minto C, Barbetta B, Gualtieri F, Azzolina D, et al. Association of pharmacological treatments with long-term pain control in patients with knee osteoarthritis: a systematic review and meta-analysis. JAMA. 2018;320:2564–2579. doi: 10.1001/jama.2018.19319.
    1. Beaudart C, Lengelé L, Leclercq V, Geerinck A, Sanchez-Rodriguez D, Bruyère O, Reginster JY. Symptomatic efficacy of pharmacological treatments for knee osteoarthritis: a systematic review and a network meta-analysis with a 6-month time horizon. Drugs. 2020;80:1947–1959. doi: 10.1007/s40265-020-01423-8.
    1. Zou K, Wong J, Abdullah N, Chen X, Smith T, Doherty M, Zhang W. Examination of overall treatment effect and the proportion attributable to contextual effect in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis. 2016;75:1964–1970. doi: 10.1136/annrheumdis-2015-208387.
    1. Nakagawa Y, Tatebe M, Yamamoto M, Kurimoto S, Iwatsuki K, Hirata H. Choice of control group treatments in hand osteoarthritis trials: a systematic review and meta-analysis. Semin Arthritis Rheum. 2021;51:775–785. doi: 10.1016/j.semarthrit.2021.04.006.
    1. Kloppenburg M, Maheu E, Kraus VB, et al.; OARSI Hand Clinical Trial Recommendations Work Group (2015) OARSI Clinical Trials Recommendations: design and conduct of clinical trials for hand osteoarthritis. Osteoarthr Cartil 23:772–786. 10.1016/j.joca.2015.03.007
    1. Reginster JL, Arden NK, Haugen IK, Rannou F, Cavalier E, Bruyère O. Guidelines for the conduct of pharmacological clinical trials in hand osteoarthritis: Consensus of a Working Group of the European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) Semin Arthritis Rheum. 2018;48:1–8. doi: 10.1016/j.semarthrit.2017.12.003.
    1. Kroon FPB, van der Heijde D, Maxwell LJ, Beaton DE, Abishek A, Berenbaum F, et al. Core outcome measurement instrument selection for physical function in hand osteoarthritis using the OMERACT Filter 2.1 process. Semin Arthritis Rheum. 2021;51:1311–1319. doi: 10.1016/j.semarthrit.2021.08.014.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe